Akanda Corp. - Common Shares (AKAN)

TORONTO, ON / ACCESS Newswire / October 1, 2025 / Long-term investors love share scarcity. Shorts get restless sleep. Akanda Corp. (NASDAQ:AKAN) is now living proof of both. With fewer than a million shares in play and a national infrastructure program at its back, the company has become one of the market's rarest combinations: a tiny float strapped to a massive opportunity.

TORONTO, ON / ACCESS Newswire / October 1, 2025 / Scarcity is usually a problem in business. For Akanda Corp. (NASDAQ:AKAN), it's an advantage. The company sits on one of the leanest floats on the Nasdaq, barely 728,000 shares after its reverse split. That scarcity means every contract, every tower, and every stretch of fiber deployed carries more weight than it would anywhere else. First Towers & Fiber (FTF), now fully under the Akanda umbrella, is the engine turning that scarcity into torque.

Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers...

TORONTO, ON / ACCESS Newswire / September 30, 2025 / Owning shares in most small caps can feel like holding a lottery ticket where the odds of winning are one in millions. Many flood the market with paper, leaving individual ownership positions barely registering. Akanda Corp (NASDAQ:AKAN) flipped that script. With roughly 728,000 shares outstanding after its reverse split, its float is one of the leanest on the Nasdaq. That kind of scarcity doesn't just stand out - it ensures every operational milestone carries amplified weight.

Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") is pleased to report on the progress...

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C. LTD (the “Owner”) have agreed upon terms to purchase farming land and related operations and licenses.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that the Company has received a written notification (the “Notification Letter”) on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days.

International Medical Cannabis Company, Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda and Veridia Canada Ltd. (the “Lender”) have mutually agreed to terminate the loan agreement between the parties previously announced on April 18, 2023 (the “Loan Agreement”). Akanda has returned all funds provided under the terms of the Loan Agreement and has no further obligations owing to the Lender pursuant to the Loan Agreement.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that it has entered into a loan agreement dated April 26, 2023 (the “Loan Agreement”) with Veridia Canada Ltd. (the “Lender”), in the principal amount of €500,000 (approximately C$738,650) (the “Loan”), which has been advanced in full by the Lender. The Loan is expected to be used for the short-term financial commitments of Akanda and Akanda’s wholly-owned company in Portugal, RPK Biopharma, Unipessoal, LDA (“RPK”), which is indirectly held by Akanda through Holigen Limited (“Holigen”). Holigen is a directly held, wholly-owned subsidiary of the Company.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, today announced that it received a notification letter (the “Notification Letter on Compliance”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”) dated March 27, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it expects to implement a 1-for-10 reverse stock split on its ordinary shares effective Thursday March 9, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will continue on the Nasdaq Capital Market under the symbol “AKAN”. The new CUSIP number for the ordinary shares following the reverse stock split is 00971M205.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) an Ontario company, reported that it has appointed a new Chief Financial Officer. Effective immediately Shailesh Bhushan will join the company, and comes to Akanda with more than 25 years of financial and accounting experience.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk’s Service Agreement dated June 2, 2021 (the “Service Agreement”) to an immediate end with effect from February 13th, 2023.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Tejinder Virk resigned from his position as CEO and Director of the Company. Mr. Virk notified the Company of his resignation on February 3, 2023.

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) today announced that it successfully launched its initial supply to German customers recognizing approximately €1,803,996M 1 in sales of EU GMP high-quality indoor-grown medical cannabis in the last quarter of 2022. On a preliminary, unaudited basis, Akanda has recognized its first material revenues since its inception, validating the Company’s strategy to enter the European markets supplying high-end indoor-grown cannabis. These revenues result from only two full months of sales, with the indoor facility shipping only an estimated 40% of the facility's capacity. The Company prepares for the expansion of its indoor cultivation capabilities at its Holigen facility after receiving test results for the highest percentage of THC potency in any cannabis product to be sold within Germany and forecasts sales to double over the next six months.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Chief Executive Officer Tej Virk has been on a paid leave of absence both administrative and personal since November 30, 2022, pending an independent investigation being conducted by Canmart Directors and counsel. During his leave, Mr. Virk is not expected to perform any responsibilities as the Chief Executive Officer of the Company or any responsibilities as an officer of any of the Company’s subsidiaries.

Medical cannabis cultivation company Akanda Corp. ("Akanda" or the "Company") (NASDAQ: AKAN) (Frankfurt: Y23) is affirming a shift in strategy to become a significant player as a premium EU GMP cultivator in Europe, targeting 10% market share in the German medical cannabis flower market in the near term. Akanda also has a cultivation and dispensary licensing deal with Cookies® in Portugal. These steps put Akanda on firm footing to serve the future regulated adult-use markets in Europe once established.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it sees its first export shipment arrive from its Portugal-based operation and announces the first sale has been achieved, solidifying the company as operationally profitable in the market. Akanda recently entered into an agreement to deliver at least 1,000 kilograms of high-grade medical cannabis flower to Germany through the Cansativa platform. The deal ranks as one of the largest supply agreements in the European medical cannabis industry. Cansativa is also the only company in Germany permitted to distribute domestically grown cannabis.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that the Company has received a written notification (the “Notification Letter”) on September 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it prepares for first export shipment from its Portugal-based Holigen operation in the coming weeks. Akanda’s EU GMP certified indoor grow facility in Sintra received its first purchase order and is expected to make its first export shipment to Germany imminently. Akanda recently entered into an agreement to deliver 1,000 kilograms of high-grade medical cannabis flower to German pharmacies through the Cansativa platform. Cansativa is the only company in Germany permitted to distribute domestically grown cannabis. Cansativa will have a right of first refusal (ROFR) to take on additional quantities that could result in the full capacity utilization of Holigen’s 2,000 kilograms per annum indoor production capacity. The deal ranks as one of the largest supply agreements in the European medical cannabis industry.

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced an exclusive license agreement with iconic international cannabis lifestyle brand Cookies. The multi-year agreement enables Akanda to pursue the current medical and future adult-use opportunities in Europe with arguably one of the best-known cannabis brands and highest quality genetics in the world.

International cannabis company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced that Terry Booth, the founder of Aurora Cannabis Inc. (“Aurora Cannabis”) (NASDAQ:ACB) has joined Akanda as a Chair of Akanda’s newly formed Advisory Board.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced that Chief Executive Officer Tej Virk will attend the Benzinga Cannabis Capital Conference in Chicago on September 13 and 14. Virk will speak on an expert panel with executives from other international cannabis companies and be available for 1x1 meetings with investors and media throughout the event.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced that it has appointed Tom Flow to the role of Chief Operating Officer of Akanda and Managing Director of Holigen, and Steven George to the role of Commercial Director, effective September 1, 2022. The Company believes that these two hires will enhance its leadership direction and boost profitability across the European medical cannabis market.

International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced it has signed a multi-year supply agreement with European medical cannabis leader Cansativa GmbH (“Cansativa Group” or “Cansativa”) to supply EU-GMP quality THC dried flower strains cultivated from its Portuguese operations at Holigen. This new supply agreement marks one of the largest for medical cannabis to be exported from Portugal to serve the emerging European medical cannabis market.